ImmunityBio (NASDAQ:IBRX) Shares Gap Up to $1.43

Shares of ImmunityBio, Inc. (NASDAQ:IBRX – Get Rating) gapped up before the market opened on Thursday . The stock had previously closed at $1.43, but opened at $1.46. ImmunityBio shares last traded at $1.30, with a volume of 338,035 shares changing hands.

ImmunityBio Price Performance

The company’s 50-day moving average is $3.32 and its 200 day moving average is $4.62.

Hedge Funds Weigh In On ImmunityBio

Several hedge funds and other institutional investors have recently modified their holdings of IBRX. Swiss National Bank raised its position in shares of ImmunityBio by 9.2% in the 1st quarter. Swiss National Bank now owns 188,000 shares of the company’s stock valued at $1,055,000 after purchasing an additional 15,900 shares during the last quarter. MetLife Investment Management LLC raised its position in shares of ImmunityBio by 28.5% in the 1st quarter. MetLife Investment Management LLC now owns 33,258 shares of the company’s stock valued at $187,000 after purchasing an additional 7,377 shares during the last quarter. Charles Schwab Investment Management Inc. raised its position in shares of ImmunityBio by 3.5% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 493,059 shares of the company’s stock valued at $2,767,000 after purchasing an additional 16,672 shares during the last quarter. Vident Investment Advisory LLC raised its position in shares of ImmunityBio by 19.7% in the 1st quarter. Vident Investment Advisory LLC now owns 201,588 shares of the company’s stock valued at $1,131,000 after purchasing an additional 33,112 shares during the last quarter. Finally, State Street Corp raised its position in shares of ImmunityBio by 8.8% in the 1st quarter. State Street Corp now owns 6,760,306 shares of the company’s stock valued at $37,925,000 after purchasing an additional 544,929 shares during the last quarter. 9.86% of the stock is owned by hedge funds and other institutional investors.

About ImmunityBio

(Get Rating)

ImmunityBio, Inc is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company’s immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory.